PDCD1 and lung carcinoma: However, most of these studies were single-center and had small sample sizes, so more multi-center studies are needed to provide further data support.<h4>Conclusion</h4>TD resulting from PD-1/PD-L1 inhibitor treatment in advanced lung cancer may be associated with good clinical outcomes.